Status:

COMPLETED

Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors

Lead Sponsor:

Frederick R. Ueland, M.D.

Collaborating Sponsors:

Lucille P. Markey Cancer Center at University of Kentucky

Conditions:

Ovarian Neoplasms

Eligibility:

FEMALE

25+ years

Phase:

NA

Brief Summary

The present investigation will prospectively evaluate whether serial transvaginal ultrasonography with Morphology Index (MI) can further reduce false positive results by more accurately distinguishing...

Detailed Description

Primary Objective: To determine if a treatment algorithm using serial transvaginal ultrasound with a tumor morphology index can improve the positive predictive value (PPV) of ovarian cancer screening...

Eligibility Criteria

Inclusion

  • Women must be enrolled in the University of Kentucky Ovarian Cancer Screening Program Eligibility criteria for the OCSP are: 50 years of age or older, or be postmenopausal and have not had a prior salpingo-oophorectomy or have a family history of ovarian cancer in a primary relative or have a self-history of breast cancer.
  • Patients have a documented ovarian abnormality on ultrasound
  • Patients having undergone prior hysterectomy will be eligible provided that they meet the other requirements for entry into this study.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion

  • Patients who are not enrolled in the University of Kentucky Ovarian Cancer Screening Program .
  • Patients who cannot tolerate the vaginal ultrasound procedure.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients who are referred with pelvic symptoms, a known pelvic mass, or a history of prior radiation, will be excluded from this investigation.
  • History of ovarian cancer.
  • Prior bilateral salpingo-oophorectomy.
  • Prisoners.
  • Women who are currently pregnant.

Key Trial Info

Start Date :

September 12 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 7 2022

Estimated Enrollment :

179 Patients enrolled

Trial Details

Trial ID

NCT02227654

Start Date

September 12 2016

End Date

September 7 2022

Last Update

March 2 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Markey Cancer Center, University of Kentucky

Lexington, Kentucky, United States, 40536